The Manufacturers Life Insurance Company Purchases 1,360 Shares of Omnicell, Inc. (NASDAQ:OMCL)

The Manufacturers Life Insurance Company raised its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 23,459 shares of the company’s stock after buying an additional 1,360 shares during the period. The Manufacturers Life Insurance Company’s holdings in Omnicell were worth $635,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares in the last quarter. EntryPoint Capital LLC boosted its holdings in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after purchasing an additional 1,345 shares in the last quarter. CWM LLC increased its position in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares in the last quarter. Benjamin Edwards Inc. raised its position in Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Omnicell in the second quarter valued at about $104,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Down 0.8 %

Shares of Omnicell stock opened at $42.38 on Wednesday. The business has a 50-day moving average price of $43.12 and a 200 day moving average price of $34.04. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $45.84. The firm has a market cap of $1.95 billion, a P/E ratio of -92.13, a P/E/G ratio of 47.35 and a beta of 0.83. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The business’s revenue was down 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on OMCL shares. JPMorgan Chase & Co. increased their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Bank of America raised their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Barclays upgraded Omnicell from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $26.00 to $39.00 in a report on Friday, August 2nd. Wells Fargo & Company lifted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, October 10th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.